Zydus to back Microbix's urokinase relaunch plans in North America
This article was originally published in Scrip
Executive Summary
The Canadian firm, Microbix Biosystems, will receive financial backing and regulatory support from Zydus Cadila of India for the proposed relaunch of the thrombolytic drug, urokinase, in the North America.